Form 4: Community Health Systems CFO Kevin Hammons Reports Stock Transactions
SEC Form 4 Filing
Kevin Hammons, CFO of Community Health Systems, reports the vesting and acquisition of shares, as well as the forfeiture of some performance-based restricted shares, in a recent Form 4 filing.
Summary
- Kevin Hammons, the President and CFO of Community Health Systems Inc., filed a Form 4 on March 1, 2024, detailing changes in his beneficial ownership of the company's stock.
- The filing reports the vesting of 120,000 performance-based restricted shares, the acquisition of 90,000 shares of restricted stock, and the forfeiture of 30,000 performance-based restricted shares.
- The vesting of the 120,000 performance-based restricted shares was based on the attainment of certain performance objectives between January 1, 2021, and December 31, 2023, at 80% of the target number.
- Hammons also acquired 90,000 shares of restricted stock that will vest in equal installments over three years.
- Additionally, he acquired 90,000 stock options with an exercise price of $2.87, exercisable starting March 1, 2024, and expiring on February 28, 2034.
- The filing also covers various other stock options held by Hammons with different exercise prices and expiration dates.
- 78,701 shares were disposed of at a price of $2.87.
- Hammons now directly owns 564,366 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While there's vesting of shares (positive), there's also forfeiture (negative). The overall impact is likely minimal as it's a routine executive compensation disclosure.
Positives
- The vesting of performance-based restricted shares suggests that some performance objectives were met during the 2021-2023 period.
- The acquisition of additional restricted stock and stock options indicates continued investment and alignment with the company's future performance.
Negatives
- The forfeiture of 30,000 performance-based restricted shares indicates that certain performance objectives were not fully achieved during the 2021-2023 period.
Risks
- Future vesting of performance-based restricted shares is contingent on achieving pre-determined performance objectives, including Cumulative Consolidated Adjusted EBITDA Growth, Cumulative Same-Store Net Revenue Growth, and Total Shareholder Return (TSR) Percentile Rank.
- The value of the stock options is dependent on the future stock price of Community Health Systems.
Future Outlook
Future vesting of performance-based restricted shares depends on the company's performance against pre-determined objectives over the next several years (2022-2024, 2023-2025, and 2024-2026 Performance Periods).
Industry Context
Form 4 filings are routine disclosures for company insiders and provide transparency into their transactions in the company's stock. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Comparing Community Health Systems to other for-profit hospital operators like HCA Healthcare (HCA) and Tenet Healthcare (THC), executive compensation structures often include a mix of salary, stock options, and performance-based restricted stock units (RSUs).
- The specific performance metrics used for vesting RSUs, such as EBITDA growth, revenue growth, and TSR, are common in the healthcare industry to align executive incentives with shareholder value creation.
- The vesting schedules and performance periods (e.g., 2021-2023, 2022-2024, 2023-2025) are typical for long-term incentive plans in publicly traded companies.
- The percentage of target achievement (e.g., 80% for the 2021-2023 performance period) is also a standard way to adjust the number of shares vesting based on actual performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of shares outstanding.
- The vesting of performance-based shares suggests that management is incentivized to achieve certain performance goals, which could benefit shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/01/2020 | Date of grant for some stock options |
| 03/01/2021 | Date of grant for some stock options |
| 01/01/2021 | Start of the 2021-2023 Performance Period |
| 03/02/2021 | Date performance-based restricted shares originally reported |
| 03/01/2022 | Date of grant for some stock options |
| 01/01/2022 | Start of the 2022-2024 Performance Period |
| 03/01/2023 | Date of grant for some stock options |
| 01/01/2023 | Start of the 2023-2025 Performance Period |
| 09/18/2023 | Date of execution of Power of Attorney |
| 12/31/2023 | End of the 2021-2023 Performance Period |
| 03/01/2024 | Date of Earliest Transaction, vesting of performance-based restricted shares, acquisition of restricted stock and stock options, and filing of Form 4 |
| 01/01/2024 | Start of the 2024-2026 Performance Period |
| 02/28/2029 | Expiration date for some stock options |
| 02/28/2030 | Expiration date for some stock options |
| 02/28/2031 | Expiration date for some stock options |
| 02/29/2032 | Expiration date for some stock options |
| 02/28/2033 | Expiration date for some stock options |
| 02/28/2034 | Expiration date for some stock options |
| 12/31/2024 | End of the 2022-2024 Performance Period |
| 12/31/2025 | End of the 2023-2025 Performance Period |
| 12/31/2026 | End of the 2024-2026 Performance Period |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.